Chengfei Liu

3.6k total citations · 1 hit paper
71 papers, 2.6k citations indexed

About

Chengfei Liu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Chengfei Liu has authored 71 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 29 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Chengfei Liu's work include Prostate Cancer Treatment and Research (44 papers), Cancer-related gene regulation (8 papers) and Aldose Reductase and Taurine (7 papers). Chengfei Liu is often cited by papers focused on Prostate Cancer Treatment and Research (44 papers), Cancer-related gene regulation (8 papers) and Aldose Reductase and Taurine (7 papers). Chengfei Liu collaborates with scholars based in United States, China and United Kingdom. Chengfei Liu's co-authors include Allen C. Gao, Wei Lou, Christopher P. Evans, Yezi Zhu, Nagalakshmi Nadiminty, Cameron M. Armstrong, Joy C. Yang, Ramakumar Tummala, Alan P. Lombard and Chad Schwartz and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chengfei Liu

67 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dietary sugar consumption and health: umbrella review

2023 156 citations Chengfei Liu, Qiang Wei et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chengfei Liu United States	28	1.3k	1.2k	643	519	351	71	2.6k
Masaki Shiota Japan	39	2.0k 1.5×	2.3k 1.9×	1.1k 1.6×	945 1.8×	508 1.4×	253	4.3k
Dong Lin Canada	30	1.1k 0.8×	1.7k 1.5×	1.0k 1.6×	593 1.1×	100 0.3×	99	2.9k
Paul Thelen Germany	27	594 0.4×	1.1k 0.9×	386 0.6×	306 0.6×	153 0.4×	83	2.0k
Imran Ahmad United Kingdom	36	613 0.5×	2.0k 1.7×	670 1.0×	648 1.2×	57 0.2×	123	3.4k
Venkateshwar G. Keshamouni United States	31	476 0.4×	2.0k 1.7×	698 1.1×	800 1.5×	85 0.2×	49	3.5k
Peter Ellinghaus Germany	28	380 0.3×	1.6k 1.4×	544 0.8×	444 0.9×	96 0.3×	74	3.1k
Paola Ferrari Italy	28	340 0.3×	957 0.8×	496 0.8×	837 1.6×	118 0.3×	103	2.6k
Taoufik Ouatas United States	23	463 0.3×	866 0.7×	185 0.3×	337 0.6×	204 0.6×	38	1.8k
Hiroshi Eto Japan	28	596 0.4×	963 0.8×	432 0.7×	513 1.0×	74 0.2×	96	2.5k

Countries citing papers authored by Chengfei Liu

Since Specialization

Citations

This map shows the geographic impact of Chengfei Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengfei Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengfei Liu more than expected).

Fields of papers citing papers by Chengfei Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengfei Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengfei Liu. The network helps show where Chengfei Liu may publish in the future.

Co-authorship network of co-authors of Chengfei Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Chengfei Liu. A scholar is included among the top collaborators of Chengfei Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengfei Liu. Chengfei Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ning, Shu, Wei Lou, Pui‐Kai Li, et al.. (2025). Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer. Cancers. 17(12). 1959–1959. 1 indexed citations

Tian, Yao, Huiyang Gao, Yanli Wang, et al.. (2025). Development and validation of a risk prediction model related to inflammatory and nutritional indexes for postoperative pulmonary infection after radical colorectal cancer surgery. BMJ Open. 15(1). e087426–e087426. 2 indexed citations

Ning, Shu, Wei Lou, Alan P. Lombard, et al.. (2024). PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells. Cancer Research Communications. 4(11). 2976–2985.

Chen, Bo, Pengfei Xu, Joy C. Yang, et al.. (2024). Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene. 43(30). 2325–2337. 3 indexed citations

Ning, Shu, Enming Xing, Wei Lou, et al.. (2024). LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy. Cancer Research. 84(21). 3617–3628. 4 indexed citations

Ning, Shu, Cameron M. Armstrong, Leandro S. D’Abronzo, et al.. (2024). IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience. 27(2). 108984–108984. 6 indexed citations

Ning, Shu, Cameron M. Armstrong, Wei Lou, et al.. (2023). Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer. Cancers. 15(21). 5273–5273. 3 indexed citations

Xu, Pengfei, Joy C. Yang, Bo Chen, et al.. (2023). Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. Journal for ImmunoTherapy of Cancer. 11(5). e006581–e006581. 24 indexed citations

Liu, Chengfei, et al.. (2023). CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. Biomedicines. 11(12). 3326–3326. 9 indexed citations

10.

Ning, Shu, Chengfei Liu, Wei Lou, et al.. (2022). Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Molecular Cancer Therapeutics. 21(10). 1594–1607. 16 indexed citations

11.

Liu, Chengfei, et al.. (2022). Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma. Journal of Personalized Medicine. 13(1). 13–13.

12.

Armstrong, Cameron M., Chengfei Liu, Liangren Liu, et al.. (2020). Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clinical Cancer Research. 26(22). 6064–6074. 17 indexed citations

13.

Liu, Chengfei, Joy C. Yang, Cameron M. Armstrong, et al.. (2019). AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Molecular Cancer Therapeutics. 18(10). 1875–1886. 53 indexed citations

14.

Cucchiara, Vito, Joy C. Yang, Chengfei Liu, et al.. (2019). GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Molecular Cancer Therapeutics. 18(10). 1811–1821. 10 indexed citations

15.

Wang, Yongqiang, Zenghong Huang, Chengfei Liu, et al.. (2019). Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs. Molecular Cancer Therapeutics. 19(2). 364–374. 19 indexed citations

16.

Liu, Chengfei, Cameron M. Armstrong, Wei Lou, et al.. (2017). Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Molecular Cancer Therapeutics. 16(8). 1521–1530. 54 indexed citations

17.

Liu, Yale, Lingling Peng, Liang Li, et al.. (2017). TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid. Journal of Investigative Dermatology. 137(7). 1512–1522. 39 indexed citations

18.

Nadiminty, Nagalakshmi, Ramakumar Tummala, Chengfei Liu, et al.. (2015). NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Molecular Cancer Therapeutics. 14(8). 1884–1895. 100 indexed citations

19.

Zhu, Yezi, Chengfei Liu, Nagalakshmi Nadiminty, et al.. (2013). Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer. Molecular Cancer Therapeutics. 12(9). 1829–1836. 104 indexed citations

20.

Nadiminty, Nagalakshmi, Ramakumar Tummala, Chengfei Liu, et al.. (2013). NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants. Molecular Cancer Therapeutics. 12(8). 1629–1637. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact